TY  - JOUR
A1  - Bazarganipour, Sarah
A1  - Hausmann, Johannes
A1  - Oertel, Stephanie
A1  - El-Hindi, Khadija
A1  - Brachtendorf, Sebastian
A1  - Blumenstein, Irina Ursula
A1  - Kubesch, Alica
A1  - Sprinzl, Kathrin
A1  - Birod, Kerstin
A1  - Hahnefeld, Lisa Katharina
A1  - Trautmann, Sandra
A1  - Thomas, Dominique Jeanette
A1  - Herrmann, Eva
A1  - Geisslinger, Gerd
A1  - Schiffmann, Susanne
A1  - Grösch, Sabine
T1  - The lipid status in patients with ulcerative colitis : Sphingolipids are disease-dependent regulated
T2  - Journal of Clinical Medicine
N2  - The factors that contribute to the development of ulcerative colitis (UC), are still not fully identified. Disruption of the colon barrier is one of the first events leading to invasion of bacteria and activation of the immune system. The colon barrier is strongly influenced by sphingolipids. Sphingolipids impact cell–cell contacts and function as second messengers. We collected blood and colon tissue samples from UC patients and healthy controls and investigated the sphingolipids and other lipids by LC-MS/MS or LC-QTOFMS. The expression of enzymes of the sphingolipid pathway were determined by RT-PCR and immunohistochemistry. In inflamed colon tissue, the de novo-synthesis of sphingolipids is reduced, whereas lactosylceramides are increased. Reduction of dihydroceramides was due to posttranslational inhibition rather than altered serine palmitoyl transferase or ceramide synthase expression in inflamed colon tissue. Furthermore, in human plasma from UC-patients, several sphinglipids change significantly in comparison to healthy controls. Beside sphingolipids free fatty acids, lysophosphatidylcholines and triglycerides changed significantly in the blood of colitis patients dependent on the disease severity. Our data indicate that detraction of the sphingolipid de novo synthesis in colon tissue might be an important trigger for UC. Several lipids changed significantly in the blood, which might be used as biomarkers for disease control; however, diet-related variabilities need to be considered.
KW  - ceramide
KW  - sphingolipid
KW  - ulcerative colitis
KW  - LC–MS/MS
KW  - S1P
KW  - EPA
KW  - DHA
KW  - patient
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/51260
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-512600
SN  - 2077-0383
N1  - This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
VL  - 8
IS  - 7, Art. 971
SP  - 1
EP  - 19
PB  - MDPI
CY  - Basel
ER  -